Thrombolytic use in select stroke patients with recent direct oral anticoagulant (DOAC) ingestion did not raise the risk of the most feared bleeding complication, according to the largest-yet ...

The prevalence of inappropriate direct oral anticoagulant (DOAC) dosing in patients with atrial fibrillation (AF) was 25%. Several demographic factors such as advanced age, presence of chronic kidney ...

Despite concerns about the potential bleeding risk, IV thrombolysis could be safely given to ischemic stroke patients within a day of direct oral anticoagulant (DOAC) therapy, according to ...

Adoption of DOAC population management tool dashboard before July 2018 linked to decline in off-label dosing prescriptions HealthDay News — Early adoption of the direct oral anticoagulant (DOAC) ...

In patients with atrial fibrillation with low thrombosis risk but high bleeding risk, both standard- and low-dose DOACs are equally effective and safe. Standard-dose direct oral anticoagulant therapy ...

Apixaban or rivaroxaban may be no safer than warfarin with respect to fracture risk in patients with CKD and atrial fibrillation. Despite earlier favorable reports, fracture risk is comparable between ...

Prescriptions for treatment of atrial fibrillation (AF) and chronic kidney disease (CKD) have primarily been prescriptions for direct oral anticoagulants (DOACs), displacing warfarin as the primary ...

The risk for death goes up for patients with atrial fibrillation (AF) who are put on direct oral anticoagulants (DOAC) at dosages other than those approved for stroke prevention, whether higher or ...

In a recent study published in JAMA Network Open, researchers compared outcomes related to three direct oral anticoagulant (DOAC) care models to prevent anticoagulation-associated adverse effects ...

Among patients hospitalized for atrial fibrillation (AF) or flutter, prescription of an off-label dose of a direct oral anticoagulant (DOAC) at discharge remains relatively common, according to data ...

In everyday practice, patients with atrial fibrillation or flutter who are newly started on apixaban (Eliquis; Bristol-Myers Squibb) have lower ischemic and bleeding risks compared with those started ...